Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Curr Opin HIV AIDS. 2012 Mar;7(2):99-105. doi: 10.1097/COH.0b013e32834f5cf2.
This review summarizes the development and implementation of a large clinical trial, HIV Prevention Trials Network (HPTN) 052, whose initial results were recently presented and published.
A randomized, clinical trial demonstrated that antiretroviral therapy reduces the sexual transmission of HIV in HIV-serodiscordant couples by more than 96%. The logistical challenges in preparing for and conducting such a trial were considerable.
HPTN 052 required many years of preparation, considerable collaboration between National Institute of Health and six pharmaceutical companies, and careful ongoing consideration of a large number of ethical issues. HPTN 052 revealed the magnitude of benefit when using antiretroviral therapy to prevent the transmission of HIV, and served as proof of a concept. The results have proven central to the development of new global HIV-prevention efforts.
本文总结了一项大型临床试验——艾滋病预防试验网络（HIV Prevention Trials Network，HPTN）052 的开展和实施情况，该试验的初步结果最近公布。
一项随机临床试验表明，抗逆转录病毒疗法可使 HIV 血清不一致的夫妇间 HIV 的性传播减少 96%以上。为准备和开展此类试验而面临的后勤挑战相当大。
HPTN 052 试验需要多年的筹备，美国国立卫生研究院与六家制药公司之间进行了大量合作，并持续认真考虑了许多伦理问题。HPTN 052 试验揭示了使用抗逆转录病毒疗法预防 HIV 传播的巨大益处，也证明了这一概念。其结果是新的全球 HIV 预防工作的核心。
